Literature DB >> 6231047

Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.

N Lee, N Russell, K Ganeshaguru, B F Jackson, A Piga, H G Prentice, R Foa, A V Hoffbrand.   

Abstract

Deoxyadenosine (AdR) appears to be central to the molecular events mediating immunodeficiency in children born with adenosine deaminase (ADA) deficiency but it is still uncertain whether lymphotoxicity is due to AdR directly inhibiting transmethylation reactions in which S-adenosylmethionine is the methyl group donor, or is due to phosphorylation of AdR to deoxyadenosine triphosphate (dATP) which then inhibits ribonucleotide reductase or is due to other mechanisms. Using AdR and the ADA inhibitor deoxycoformycin (dCF) and assessing cell viability, nucleoside incorporation into RNA and DNA, as well as measuring deoxyribonucleoside triphosphate (dNTP) concentrations and S-adenosylhomocysteine (SAH) hydrolase activity, we have studied various types of human lymphoid cells and demonstrated in them the relative importance of the above two mechanisms of AdR toxicity. Treatment of normal resting peripheral blood lymphocytes in culture with AdR and dCF resulted in impaired viability. Although elevated dATP levels as well as decreased SAH hydrolase activities were both observed, the failure of a known inhibitor of ribonucleotide reductase (hydroxyurea) to produce toxicity, and the inability of deoxycytidine (CdR) to achieve a rescue effect, point to another mechanism, possibly inhibition of trans-methylation or ATP depletion being the more likely causes of toxicity in resting lymphocytes. The same mechanism may well account for the rapid and severe lymphopenia in patients treated with dCF. On the other hand, in cultured lymphoblasts in the exponential phase of growth. AdR and dCF produced marked inhibition of growth and cell death both in a Thy-ALL line and in a c-ALL line, in the absence of significant inhibition of SAH hydrolase, but with a substantial elevation in dATP concentrations and depressed levels of the other dNTP. Minor toxicity occurred in a proliferating B lymphoblast line despite almost complete inactivation of SAH hydrolase. These observations indicate inhibition of ribonucleotide reductase as the more likely mechanism of toxicity in rapidly proliferating lymphocytes. Other T-cells actively synthesizing DNA, such as PHA-stimulated or MLC activated lymphocytes and T-lymphoid colony forming cells, are also likely to be affected by the same mechanism. Indeed in PHA-stimulated lymphocytes, deoxycytidine caused significant although incomplete rescue from toxicity due to dCF and AdR. In patients with ADA deficiency or treated with ADA inhibitors, both mechanisms could be operative. These observations are also relevant to the possible use of dCF and AdR as immunosuppressive agents and for the removal of T-cells or residual Thy-ALL blasts from bone marr

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231047     DOI: 10.1111/j.1365-2141.1984.tb01276.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.

Authors:  Zhao-Wei Gao; Lan Yang; Chong Liu; Xi Wang; Wen-Tao Guo; Hui-Zhong Zhang; Ke Dong
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

Review 2.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

Review 3.  How I treat ADA deficiency.

Authors:  H Bobby Gaspar; Alessandro Aiuti; Fulvio Porta; Fabio Candotti; Michael S Hershfield; Luigi D Notarangelo
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

4.  The effect of G2-treatments with 2'-deoxyadenosine on the frequency of chromatid aberrations in human lymphocytes depends on the type of culture.

Authors:  B A Kihlman; H C Andersson
Journal:  Chromosoma       Date:  1984       Impact factor: 4.316

5.  Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy.

Authors:  Federico A Moretti; Giuliana Giardino; Teresa C H Attenborough; Athina Soragia Gkazi; Ben K Margetts; Giancarlo la Marca; Lynette Fairbanks; Tessa Crompton; H Bobby Gaspar
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

6.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).

Authors:  Claire Booth; H Bobby Gaspar
Journal:  Biologics       Date:  2009-07-13

7.  Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms.

Authors:  Barbara Kutryb-Zajac; Patrycja Koszalka; Paulina Mierzejewska; Alicja Bulinska; Magdalena A Zabielska; Karolina Brodzik; Aleksandra Skrzypkowska; Lukasz Zelazek; Iwona Pelikant-Malecka; Ewa M Slominska; Ryszard T Smolenski
Journal:  J Cell Mol Med       Date:  2018-10-05       Impact factor: 5.310

Review 8.  Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency.

Authors:  Claudia A Montiel-Equihua; Adrian J Thrasher; H Bobby Gaspar
Journal:  Stem Cells Cloning       Date:  2009-12-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.